Literature DB >> 28727136

A multidimensional view of racial differences in access to prostate cancer care.

Craig Evan Pollack1,2, Katrina A Armstrong3, Nandita Mitra4, Xinwei Chen5, Katelyn R Ward5, Archana Radhakrishnan6, Michelle S Wong2, Justin E Bekelman7, Charles C Branas4, Karin V Rhodes8, David T Grande5.   

Abstract

BACKGROUND: Racial disparities in prostate cancer treatment and outcomes are widespread and poorly understood. In the current study, the authors sought to determine whether access to care, measured across multiple dimensions, contributed to racial differences in prostate cancer.
METHODS: The Philadelphia Area Prostate Cancer Access Study (P2 Access) included 2374 men diagnosed with localized prostate cancer between 2012 and 2014. Men were surveyed to assess their experiences accessing care (response rate of 51.1%). The authors determined appointment availability at 151 urology practices using simulated patient telephone calls and calculated travel distances using geospatial techniques. Multivariable logistic regression models were used to determine the association between 5 different domains of access (availability, accessibility, accommodation, affordability, and acceptability) and receipt of treatment, perceived quality of care, and physician-patient communication.
RESULTS: There were 1907 non-Hispanic white and 394 black men in the study cohort. Overall, approximately 85% of the men received definitive treatment with no differences noted by race. Black men were less likely to report a high quality of care (69% vs 81%; P<.001) and good physician-patient communication (60% vs 71%; P<.001) compared with white men. In adjusted models, none of the 5 domains of access were found to be associated with definitive treatment overall or with radical prostatectomy. All access domains were associated with perceived quality of care and communication, although these domains did not mediate racial disparities.
CONCLUSIONS: To the authors' knowledge, the current study presents the first comprehensive assessment of prostate cancer care access, treatment, and patient experience, demonstrating that although access was related to overall perceived quality of care and better physician-patient communication, it did not appear to explain observed racial differences. Cancer 2017;123:4449-57.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  access to care; definitive treatment; prostate cancer; prostate cancer treatment; racial disparities

Mesh:

Year:  2017        PMID: 28727136      PMCID: PMC5673580          DOI: 10.1002/cncr.30894

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Geographic Access to Mammography and Its Relationship to Breast Cancer Screening and Stage at Diagnosis: A Systematic Review.

Authors:  Jenna A Khan-Gates; Jennifer L Ersek; Jan M Eberth; Swann A Adams; Sandi L Pruitt
Journal:  Womens Health Issues       Date:  2015-07-26

2.  Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urol Oncol       Date:  2016-05-06       Impact factor: 3.498

3.  A framework for the study of access to medical care.

Authors:  L A Aday; R Andersen
Journal:  Health Serv Res       Date:  1974       Impact factor: 3.402

4.  Exploring dimensions of access to medical care.

Authors:  R M Andersen; A McCutcheon; L A Aday; G Y Chiu; R Bell
Journal:  Health Serv Res       Date:  1983       Impact factor: 3.402

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

7.  Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.

Authors:  Chun Chieh Lin; Suanna S Bruinooge; M Kelsey Kirkwood; Christine Olsen; Ahmedin Jemal; Dean Bajorin; Sharon H Giordano; Michael Goldstein; B Ashleigh Guadagnolo; Michael Kosty; Shane Hopkins; James B Yu; Anna Arnone; Amy Hanley; Stephanie Stevens; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Association between travel distance and metastatic disease at diagnosis among patients with colon cancer.

Authors:  Nader N Massarweh; Yi-Ju Chiang; Yan Xing; George J Chang; Alex B Haynes; Y Nancy You; Barry W Feig; Janice N Cormier
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

9.  Predicting 10-year mortality for older adults.

Authors:  Marisa Cruz; Kenneth Covinsky; Eric W Widera; Irena Stijacic-Cenzer; Sei J Lee
Journal:  JAMA       Date:  2013-03-06       Impact factor: 56.272

10.  Geographic access to breast imaging for US women.

Authors:  Tracy Onega; Rebecca Hubbard; Deirdre Hill; Christoph I Lee; Jennifer S Haas; Heather A Carlos; Jennifer Alford-Teaster; Andy Bogart; Wendy B DeMartini; Karla Kerlikowske; Beth A Virnig; Diana S M Buist; Louise Henderson; Anna N A Tosteson
Journal:  J Am Coll Radiol       Date:  2014-06-02       Impact factor: 5.532

View more
  2 in total

Review 1.  Disparities in the Utilization of Radiation Therapy for Prostate Cancer in the United States: A Comprehensive Review.

Authors:  Ulysses Gardner; Shearwood McClelland; Curtiland Deville
Journal:  Adv Radiat Oncol       Date:  2022-03-18

2.  Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.

Authors:  Ming Wang; Emily Wasserman; Nathaniel Geyer; Rachel M Carroll; Shanshan Zhao; Lijun Zhang; Raymond Hohl; Eugene J Lengerich; Alicia C McDonald
Journal:  BMC Cancer       Date:  2020-05-06       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.